NCT06448013View on ClinicalTrials.gov

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

Given by PO

DRUG

Gemtuzumab

Given by IV

DRUG

Ziftomenib

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Kura Oncology, Inc.
All Listed Sponsors
collaborator

Kura Oncology, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER